The psychedelic-themed event will be hosted by Proactive’s Christine Corrado and kicks off on Tuesday at 1.00pm ET.
Silo Pharma: bridging the gap
Silo Pharma is bridging the gap between traditional pharmaceuticals and the emerging psychedelics space.
The developmental-stage biopharmaceutical company’s mission is to identify assets to license and fund the research which it believes could transform both the well-being of patients and the healthcare system at large.
“In these uncertain times, the mental health of the nation and beyond is being put to the test. More than ever, creative new therapies and lines of thought are needed to address health challenges of today,” Silo has said “Combining our resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space.”
The company’s management and founders have played key roles in numerous successful biotech companies. CEO Eric Weisblum will share the company’s story and strategies for success at Tuesday’s event.
Lobe Sciences: advancing transformational treatments for brain injuries
Lobe Sciences is mastering the development of transformational medicines and devices as it builds a growing portfolio of intellectual property to support wellness and improve mental health.
The Vancouver-based company is currently advancing unique medicines and devices to treat mild traumatic brain injury and post-traumatic stress disorder, as well as other indications. With five provisional patents, a pre-clinical study underway and a drug delivery device in engineering development, Lobe is quickly making a name for itself in the world of psychedelics.
In December, Lobe sold its cannabis asset Cowlitz County Cannabis Cultivation to Ionic Brands, netting $23 million and a stake in the latter company to keep a foothold in the red-hot US cannabis space.
CEO Phil Young will share the company’s plans for the proceeds and Lobe's other strategic initiatives for 2021 with event participants on Tuesday.
Aion Therapeutic: using artificial intelligence to create a full lineup of psychedelic and cannabis therapies
Toronto-based Aion Therapeutic Inc (CSE:AION) recently filed five patent applications with the US Patent and Trademark Office related to the combination of medical cannabis with edible and psychedelic mushrooms.
The applications include formulations designed to treat a variety of conditions, including cancer, psychiatric disorders, addiction, viral diseases, obesity and inflammatory disorders.
Aion’s combinatorial treatment formulation discovery platform relies on artificial intelligence (AI) techniques. By utilizing AI, the company plans to create a full line of therapeutic products that includes combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals, as well as individualized treatments for personalized medicine using human genome and other data.
Executive chairman Dr Stephen Barnhill will take participants through the firm’s pharmaceutical research and product development. Aion also operations in Jamaica, where psychedelics are more available.
About the event:
- Ours is an audience of astute high net worth investors, fund managers, private client brokers and analysts
- We look beyond the numbers and meet the people creating the value for shareholders
- Each company has a presentation slot followed by Q&A, giving you the chance to discover the real story
- You can watch the event afterwards on our YouTube channel